Galapagos Proposes Name Change and Governance for Shareholder Vote
Galapagos NV has released its 2025 annual report and announced a joint ordinary general meeting and extraordinary general meeting scheduled for April 28, 2026. These shareholder meetings will decide on several board nominations and major strategic directions.
Ordinary General Meeting Agenda
The ordinary general meeting (AGM) will be held on April 28, 2026, at 2:00 PM CET in Mechelen, Belgium. The agenda includes the appointment of Henry Gosebruch as executive director, the appointment of five independent non-executive directors (Jane Griffiths, Dawn Svoronos, Neil Johnston, Paulo Fontoura, and Gino Santini), and the appointment of Devang Bhuva as a non-executive director. The renewal of the auditor BDO Bedrijfsrevisoren is also on the agenda, along with the confirmation of their appointment for the sustainability assurance directive (CSRD).
Extraordinary General Meeting Agenda
The extraordinary general meeting (EGM) will take place on April 28, 2026, at 3:00 PM CET, immediately following the AGM. It will address the proposed company name change to 'Lakefront Biotherapeutics', the authorization to repurchase up to 10% of the outstanding shares under certain limitations, and the renewal of the board's authorization to increase the share capital within the existing capital authorization framework.
